Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher McCabe

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 1, 2007
Guidance on good practice in cost-effectiveness modeling: is more needed?Christopher McCabe
The Hastings Center Report|October 12, 2012
The many vs. the fewChristopher McCabe
Pharmacoeconomics|October 18, 2018
Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of CautionChristopher McCabe
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|December 15, 2015
Imaging the ischaemic penumbra with T2* weighted MRIChristopher McCabe
Healthcare Management Forum|September 12, 2019
Hard choices: Reflections from the tomb of the unknown patientChristopher McCabe, Jeff Round
Stem Cells and Development|December 6, 2013
Value-engineered translation for regenerative medicine: meeting the needs of health systemsTania Bubela, Christopher McCabe
The American Journal of Managed Care|April 2, 2015
Value-engineered translation: developing biotherapeutics that align with health-system needsTania Bubela, Christopher McCabe
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
How to improve the cost effectiveness of oncology drug development A commentary on Tan et al. Anti-cancer drug resistance--understanding the mechanisms through the use of integrative genomics and functional RNA interferenceChristopher McCabe, John Smyth
Cell Stem Cell|April 9, 2016
Undertested and Overpriced: Japan Issues First Conditional Approval of Stem Cell ProductChristopher McCabe, Douglas Sipp
Health Economics|May 31, 2007
'Is there a case for using visual analogue scale valuations in CUA' by Parkin and Devlin. A response: 'yes there is a case, but what does it add to ordinal data?'John Brazier, Christopher McCabe
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 1, 2007
Guidance on good practice in cost-effectiveness modeling: is more needed?Christopher McCabe
The Hastings Center Report|October 12, 2012
The many vs. the fewChristopher McCabe
Pharmacoeconomics|October 18, 2018
Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of CautionChristopher McCabe
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|December 15, 2015
Imaging the ischaemic penumbra with T2* weighted MRIChristopher McCabe
Healthcare Management Forum|September 12, 2019
Hard choices: Reflections from the tomb of the unknown patientChristopher McCabe, Jeff Round
Stem Cells and Development|December 6, 2013
Value-engineered translation for regenerative medicine: meeting the needs of health systemsTania Bubela, Christopher McCabe
The American Journal of Managed Care|April 2, 2015
Value-engineered translation: developing biotherapeutics that align with health-system needsTania Bubela, Christopher McCabe
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
How to improve the cost effectiveness of oncology drug development A commentary on Tan et al. Anti-cancer drug resistance--understanding the mechanisms through the use of integrative genomics and functional RNA interferenceChristopher McCabe, John Smyth
Cell Stem Cell|April 9, 2016
Undertested and Overpriced: Japan Issues First Conditional Approval of Stem Cell ProductChristopher McCabe, Douglas Sipp
Health Economics|May 31, 2007
'Is there a case for using visual analogue scale valuations in CUA' by Parkin and Devlin. A response: 'yes there is a case, but what does it add to ordinal data?'John Brazier, Christopher McCabe
Pageof 15